cagrisema semaglutide cagrilintide phase 3 results 2025 Novo Nordisk's outperforms Ozempic in III trial Novo's CagriSema loses phase 3

References Sikiric P

2004;32(Pt 5):8126

Blocking NNMT activity has been shown in research settings to influence body composition, leading to reduced adipocyte size, alterations in fat mass, and measurable changes in plasma biomarkers such as glucose and cholesterol

The obesity trial showed weight reductions of up to 14.7% at 36 weeks with the 45 mg dose, while the diabetes trial demonstrated HbA1c reductions of up to 2.1 percentage points and weight loss of up to 10.1 kg at 26 weeks

The development of single-inhibitor with multi-target drugs is expected to improve efficacy through synergistic effects while reducing side effects